Navigation Links
Einstein-Montefiore Center for AIDS Research receives $8.5M award from NIH
Date:5/27/2008

May 27, 2008 (BRONX, NY) The Albert Einstein College of Medicine of Yeshiva University has been awarded a five-year grant of more than $8.5 million from the National Institutes of Health (NIH). The renewal grant will fund the Einstein-Montefiore Center for AIDS Research (CFAR) at Einstein and Montefiore Medical Center, the University Hospital for the College, that together conduct some of the most important, fundamental research contributing to our understanding of how HIV infection causes AIDS, as well as develop and provide innovative treatment and support programs for patients. The increased funding received by the CFAR also renews its designation as an NIH CFAR site.

The award of this grant and the Centers designation as an NIH CFAR after a highly competitive review and selection process is a tribute to our position as one of the leading AIDS research programs in the country, says Dr. Harris Goldstein, director of the CFAR and professor of pediatrics and of microbiology & immunology, as well as Assistant Dean for Scientific Resources at Einstein and an attending physician in the Division of Allergy and Immunology at Montefiore. Our commitment to, and preeminent involvement in, AIDS research goes back more than 25 years, with Einstein and Montefiore investigators at the forefront of AIDS research and patient care since the emergence of the AIDS epidemic.

The CFAR coordinates the diverse research activities of hundreds of investigators at Einstein and Montefiore, who are working with over 70 NIH-funded faculty members representing more than 15 basic and clinical departments. The new grant will support the continued growth of AIDS research at both of the Centers research sites, in particular research programs involved in investigating three Core areas: HIV biology and therapeutics; HIV-associated pathogens and HIV-related epidemiology; and behavior and substance abuse. In addition, the grant will fund further expansion of Einstein and Montefiore International AIDS-related research and treatment programs that have been established in Rwanda, Ethiopia, South Africa, India and Guatemala.

The many contributions that Einstein and Montefiore researchers and clinicians have made to date include:

  • being among the first to describe AIDS in injection drug users and to demonstrate transmission by needle sharing and heterosexual intercourse;

  • being the first in the world to identify pediatric AIDS as a distinct disease and to establish a day-care center for children with AIDS;

  • identifying radioimmunotherapy (RIT) as a possible therapy for preventing or treating HIV infection;

  • developing a vaccine to combat extremely drug resistant tuberculosis (XDR-TB), which affects many AIDS patients in developing nations because of their impaired immune systems;

  • establishing clinics and research programs in developing nations, such as Rwanda, Ethiopia, South Africa, India and Guatemala, to provide much-needed treatment, as well as education about prevention; and

  • genetically engineering immune cells to redirect their infection-fighting ability toward killing HIV-infected cells, a strategy which could ultimately lead to an entirely new approach for combating AIDS and other viral diseases.

By its design, the CFAR is set up to facilitate interactions between, and collaborations among, Einstein and Montefiore basic and clinical investigators, said Dr. Allen M. Spiegel, The Marilyn and Stanley M. Katz Dean at Einstein. This is particularly helpful in accelerating the translation of research about how HIV causes AIDS into therapies that treat and prevent HIV infection.

From the earliest days of the AIDS epidemic, Montefiore clinicians and researchers at Einstein recognized the coming medical crisis, said Steven M. Safyer, MD, president and CEO of Montefiore. By combining our respective clinical and research expertise, we created what still stands as one of the most prestigious multi-disciplinary programs in the nation. The prestige and recognition that come with this NIH grant will enable both institutions to continue to find new ways to treat and care for patients in our community and beyond, and to share valuable knowledge with scientists and clinicians around the world, said Dr. Safyer.

The CFAR was first designated as an NIH CFAR site in 2003 and is currently one of just 20 such sites in the nation.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology
2. Harvard Pilgrim Health Care and Perot Systems Named as Best Partnership by Outsourcing Center
3. The Chopra Center Co-founders Bring Mind-Body Healing to New York City
4. Fat Spaniel String Monitoring Service Keeps Close Watch on Boulder Cancer Center Solar Array
5. Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP
6. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
7. eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results
8. Rep. Boozman, AOA Officials Tour Military Eye Care Facilities at Walter Reed Army Medical Center
9. Reproductive Science Center and Lowell General Hospital Announce Partnership in Infertility Treatment
10. Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM)
11. With age comes a sense of peace and calm, population research center study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... The Association of Home Care Coding & ... Health and Hospice ICD-10 Transition Workgroup are working closely with the American Hospital ... to address concerns over the use of 'A' as the seventh character indicating ...
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... , ... The schedule is now online for the largest and ... is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give ... of chronic illness in children. , Very recent articles have cited 1 child in ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... the ability to correct pelvic organ prolapse with the latest techniques and the ... at greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Calif. , Feb. 8, 2016  HemaFlo Therapeutics, Inc. ... (USPTO) has issued US Patent Number 9,119,880 covering the use ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ... --> Dale Peterson , PhD, HemaFlo,s founder, ... a powerful technology." --> Dale Peterson ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
(Date:2/8/2016)... 8, 2016 --> ... by Allied Market Research titled, "World Synthetic ... 2014-2020", estimates the world synthetic biology market to ... sequencing technology segment would continue to lead the ... segment, collectively, held around half of the market ...
Breaking Medicine Technology: